Table IV. Cox regression models of predictors of mortality in DLBCL patients treated with R-CHOP and CHOP.

	R-CHOP				CHOP
	Univariate model		Multiple variable model		Univariate model		Multiple variable model
Factors	HR	95% CI	HR	95% CI	HR	95% CI	HR	95% CI
Gender
Female	Reference
Male	0.86	0.57-1.31	0.88	0.57-1.36	1.22	0.87-1.72	1.55	1.07-2.24
Race
White	Reference
Black	0.93	0.56-1.59	0.83	0.46-1.48	1.58*	1.07-2.33	1.80*	1.15-2.82
Other	2.42	0.97-6.02	1.28	0.47-3.84	0.26	0.04-1.85	0.27	0.04-2.13
IPI
0-1	Reference
2	1.60	0.78-3.26	1.61	0.78-3.32	1.29	0.71-2.36	1.37	0.73-2.57
3	2.53*	1.29-5.00	2.48*	1.22-5.04	2.14*	1.25-3.65	2.38*	1.34-4.24
4-5	4.18*	2.12-8.25	3.43*	1.56-7.54	3.84*	2.20-6.70	3.47*	1.92-6.26
B-symptoms
Absent	Reference
Present	1.06	0.67-1.69	0.85	0.57-1.58	1.90*	1.31-2.76	1.61*	1.08-2.39
Insurance Type
Private +/- M/M	Reference
Medicaid	2.52*	1.35-4.72	2.54*	1.24-5.20	1.21	0.66-2.19	0.72	0.37-1.41
Medicare +/- Medicaid	1.69	0.97-2.94	1.61	0.88-2.95	1.74*	1.05-2.87	1.29*	0.76-2.21
Uninsured	0.27	0.04-1.98	0.35	0.05-2.58	1.33	0.33-5.46	0.78	0.16-3.82
Employed
No	Reference
Yes	0.82	0.49-1.38	1.24	0.69-2.21	1.08	0.61-1.9	1.29	0.69-2.37
Diagnosis Era
1992-1997	Reference
1998-2002	2.18	0.28-16.69	2.77	0.34-22.83	1.83*	1.27-2.63	2.12*	1.39-3.21
2003-2010	1.86	0.24-14.38	2.11	0.25-17.69	0.51	0.12-2.12	0.73	0.17-3.13
1981-1991	No observations				0.52	0.16-1.68	0.62	0.19-2.08
Family History Lymphoma
Absent	Reference
Present	0.81	0.39-1.68	0.79	0.37-1.69	0.76	0.33-1.72	0.81	0.34-1.94

^*Indicates statistical significance

Abbreviations: R-CHOP, rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP); HR, Hazard ratio; CI, Confidence Interval; IPI, International Prognostic Index; M/M, Medicare/Medicaid.